Ben Franklin Technology Partners of Southeastern Pennsylvania

Ben Franklin Technology Partners of Southeastern Pennsylvania, established in 1982 and based in Philadelphia, is a prominent capital provider dedicated to the technology sectors within Pennsylvania. The organization specializes in both early-stage and established companies, with a focus on enhancing the region's innovation ecosystem across information technology, health, and physical sciences. Over its 30-year history, Ben Franklin has invested in more than 2,000 technology companies and has contributed over $170 million to drive regional growth. In addition to its investment activities, Ben Franklin fosters university and industry partnerships to facilitate the commercialization of scientific discoveries, while also supporting initiatives that bolster the local entrepreneurial community.

Jonathan Beschen

Investment Director, Information Technology Investment Group

Anthony George

Venture Capital Associate, Tech Investment Group

McMillan, Adare

Chief Administrative Officer and Assistant Treasurer

Omar Mencin

Senior Director of Investments, Investment Group

Kathie Jordan Ph.D

Managing Director, Healthcare Investment Group

Past deals in TMT

MBF Therapeutics

Seed Round in 2018
MBF Therapeutics is a clinical-stage animal health company focusing on the development of gene-based, immunotherapeutic vaccines for use in veterinary medicine. Using proprietary vaccine platform and delivery system technology, MBF Therapeutics’ checkpoint inhibitor therapies have the potential of transforming the treatment of cancer and prevention of infectious diseases in companion animals and livestock.

Mitochon Pharmaceuticals

Venture Round in 2016
Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.

Mitochon Pharmaceuticals

Seed Round in 2014
Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.